Key Players Operating in The Fusion Biopsy Market Include MedCom, ESAOTE SPA, and GeoScan Medical

Fusion Biopsy Industry Overview

The global fusion biopsy market size is estimated to reach USD 1.11 billion by 2028 registering a CAGR of 11.6%, according to a new report by Grand View Research, Inc. The increasing prevalence of prostate cancer, growing demand for targeted biopsy, and the rising utilization rate of multiparametric MRI in prostate cancer care are factors expected to drive the market during the forecast period.

High sensitivity and specificity of targeted MR/Ultrasound fusion biopsy in delineating prostate lesions compared to other traditional technologies such as TRUS biopsy, PSA test, or Digital Rectal Examination is expected to contribute to the market growth. The reliability and reproducibility of the fusion biopsy system in the diagnosis of aggressive tumors is expected to make it a standard tool in prostate biopsy.

Fusion Biopsy Market Segmentation

Grand View Research has segmented the global fusion biopsy market on the basis of biopsy route, end-use, and region:

Based on the Route Insights, the market is segmented into Transrectal and Transperineal

• The transrectal segment dominated the market for fusion biopsy and accounted for the largest revenue share of 86.7% in 2020 because it was considered as the gold standard in performing prostate biopsy worldwide in the past decades.
• Transperineal fusion biopsy is an emerging trend and is expected to experience the fastest CAGR of 15.2% during the forecast period.

Based on the End-use Insights, the market is segmented into Hospitals, Diagnostic Centers, and Ambulatory Care Centers

• The hospitals segment dominated the market for fusion biopsy and held the largest revenue share of 61.0% in 2020 owing to their high purchasing power.
• The diagnostics centers segment is expected to grow at a significant rate in the market for fusion biopsy over the forecast period.
• The ambulatory care centers segment is expected to grow at the fastest rate of 12.6% during the forecast period.

Fusion Biopsy Regional Outlook

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa (MEA)

Key Companies Profile & Market Share Insights

The market for fusion biopsy is decently fragmented, with the top few players holding the majority of the share. However, increasing demand for efficient diagnostic tools in prostate cancer management is creating growth opportunities for new players to enter the market.

Some prominent players in the global Fusion Biopsy market include:

• MedCom
• ESAOTE SPA
• KOELIS
• Focal Healthcare
• GeoScan Medical
• UC-Care Medical Systems Ltd.

Order a free sample PDF of the Fusion Biopsy Market Intelligence Study, published by Grand View Research.